MarketCap
Facebook
X
Telegram
Enochian Biosciences Balance Sheet 2025-2011 | ENOB
Brief overview of Enochian Biosciences's balance sheet strength
This overview follows the five latest available annual observations between 2020 and 2024.
Assets finished at $163.1 million versus $178.1 million initially, losing -8.4%. The balance sheet contracted.
Liabilities grew faster than assets: +163.3% versus -8.4%. A substantial part of expansion was externally funded.
The equity-to-assets ratio is 80.9%, compared with 93.4% five periods ago. The balance sheet has a substantial internal cushion.
Net debt to equity stands at 0.01x; the current burden does not look excessive.
Cash equals 0.1% of the balance sheet, compared with 4.9% five periods ago. This is the readily available cushion.
Retained earnings remain negative at -$332.5 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall assessment
Enochian Biosciences's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.
Annual Balance Sheet Enochian Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
645 K | 1.12 M | -905 K | -7.93 M | -19.1 M | -1.11 M | -12.3 M | -15.6 M | -1.85 M | 79.5 K | -321 K | -2.91 M | 57 K | 4.66 K | - |
Long Term Debt |
425 K | 842 K | 776 K | 986 K | 1.24 M | 5.78 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
313 K | 494 K | 193 K | 254 K | 292 K | 271 K | - | - | - | - | 101 K | -100 K | -728 K | - | - |
Total Non Current Liabilities |
425 K | 842 K | 776 K | 5.56 M | 13.1 M | 10.5 M | 5.67 M | 22.9 M | - | - | - | - | - | - | - |
Total Current Liabilities |
29.2 M | 30.3 M | 11 M | 6.45 M | 1.89 M | 1.33 M | 1.11 M | 874 K | 2.99 M | 1.51 M | 996 K | 1.76 M | 2.13 M | 27.2 K | - |
Total Liabilities |
29.6 M | 31.2 M | 11.8 M | 12 M | 14.9 M | 11.8 M | 6.78 M | 23.8 M | 2.99 M | 1.51 M | 996 K | 1.76 M | 71.2 K | 27.2 K | 8.74 K |
Retained Earnings |
-510 M | -332 M | -244 M | -204 M | -90.9 M | -64.2 M | -52.8 M | -37.6 M | -28.7 M | -26.3 M | -24.6 M | -21.9 M | -76.3 K | -38.7 K | -8.74 K |
Total Assets |
8.23 M | 163 M | 58.3 M | 84.6 M | 190 M | 178 M | 180 M | 180 M | 4.52 M | 871 K | 2.07 M | 5.24 M | 20 K | 13.6 K | - |
Cash and Cash Equivalents |
92.7 K | 220 K | 1.87 M | 9.17 M | 20.7 M | 8.7 M | 12.3 M | 15.6 M | 3.94 M | 23.4 K | 421 K | 3.01 M | 18.8 K | 336 | - |
Book Value |
-21.3 M | 132 M | 46.5 M | 72.6 M | 175 M | 166 M | 173 M | 156 M | 1.53 M | -637 K | 1.08 M | 3.48 M | -51.3 K | -13.7 K | -8.74 K |
Total Shareholders Equity |
-21.3 M | 132 M | 46.5 M | 72.6 M | 175 M | 166 M | 173 M | 159 M | 1.53 M | -637 K | 1.08 M | 3.48 M | -1.68 M | -13.7 K | -8.74 K |
All numbers in USD currency
Quarterly Balance Sheet Enochian Biosciences
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
131 K | 214 K | 279 K | 214 K | 279 K | 425 K | 498 K | 674 K | 710 K | 842 K | 970 K | 664 K | 721 K | 776 K | 829 K | - | - | 986 K | 1.04 M | 1.08 M | 1.16 M | 1.24 M | 1.24 M | 1.39 M | 1.46 M | 1.53 M | 1.53 M | 1.67 M | 1.74 M | - | - | - | - | - | - | 38.2 K | 38.2 K | 38.2 K | 38.2 K | 38.2 K | 38.2 K | 103 K | 103 K | 101 K | 101 K | 101 K | 99.3 K | 100 K | 42.8 K | 38.2 K | 38.2 K | 728 K | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
131 K | 214 K | 279 K | 214 K | 279 K | 425 K | 498 K | 674 K | 710 K | 842 K | 22.8 M | 664 K | 721 K | 776 K | 829 K | - | - | 5.56 M | - | - | 17.1 M | 14.9 M | - | - | - | 11.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | 310 K | 333 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.64 M | - | - | - | - | - | - | - |
Total Liabilities |
19.4 M | 20.2 M | 20 M | 20.2 M | 20 M | 29.6 M | 29.3 M | 29.3 M | 23.7 M | 31.2 M | 43.7 M | 14.4 M | 10.8 M | 11.8 M | 12.6 M | - | - | 12 M | 18.9 M | 17.5 M | - | 14.9 M | 11.4 M | 10.9 M | 10.9 M | 11.8 M | 11.8 M | 7.08 M | 8.44 M | 6.78 M | 6.78 M | 25.2 M | 22.2 M | 23.8 M | 23.8 M | 5.97 M | 951 K | 2.99 M | 2.99 M | 1.72 M | 1.74 M | 1.51 M | 1.51 M | 894 K | 1.01 M | 996 K | 996 K | 1.76 M | 4.93 M | 3.35 M | 1.76 M | 2.13 M | 2.13 M | 2.13 M | 2.13 M | 4.73 M | - | - | - | - | - | - | - |
Retained Earnings |
-512 M | -509 M | -508 M | -509 M | -508 M | -510 M | -384 M | -384 M | -369 M | -332 M | -275 M | -258 M | -253 M | -244 M | -221 M | - | - | -204 M | -114 M | -108 M | -101 M | -90.9 M | -90.9 M | -69.5 M | -66.6 M | -64.2 M | -64.2 M | -58.6 M | -56.9 M | -52.8 M | -52.8 M | -51.2 M | -35.1 M | -57.9 M | -39.9 M | -29.7 M | -28.7 M | -28.4 M | -28.7 M | -28 M | -27.1 M | -26.3 M | -26.3 M | -25.3 M | -24.9 M | -24.6 M | -24.6 M | -21.9 M | -20.9 M | -20.4 M | -21.9 M | -19.5 M | -19.5 M | -19.5 M | -19.5 M | -17.4 M | - | - | - | - | - | - | - |
Total Assets |
9.86 M | 6.67 M | 6.96 M | 6.67 M | 6.96 M | 8.23 M | 118 M | 111 M | 122 M | 163 M | 212 M | 58 M | 57.6 M | 58.3 M | 78.7 M | - | - | 84.6 M | 180 M | 183 M | 184 M | 190 M | 190 M | 173 M | 175 M | 178 M | 178 M | 178 M | 181 M | 180 M | 180 M | 181 M | 181 M | 174 M | 176 M | 7.83 M | 3.71 M | 4.52 M | 4.52 M | 431 K | 945 K | 871 K | 871 K | 1.34 M | 1.73 M | 2.07 M | 2.07 M | 5.24 M | 2.55 M | 718 K | 5.24 M | 450 K | 450 K | 450 K | 450 K | 363 K | 15.5 K | 13.6 K | 13.6 K | 13.3 K | 20.9 K | - | - |
Cash and Cash Equivalents |
3.16 M | 492 K | 625 K | 492 K | 625 K | 92.7 K | 923 K | 312 K | 221 K | 220 K | 313 K | 244 K | 523 K | 1.87 M | 2.95 M | 4.12 M | 7.97 M | 9.17 M | 11.2 M | 13.7 M | 15.4 M | 20.7 M | 20.7 M | 3.43 M | 5.7 M | 3.43 M | 5.97 M | 8.63 M | 11.1 M | 8.63 M | 11.1 M | 13.2 M | 13.4 M | 13.2 M | 13.4 M | 2.31 M | 2.94 M | 2.31 M | 2.94 M | 118 K | 31.7 K | 118 K | 31.7 K | 531 K | 1.05 M | 531 K | 1.05 M | 3.01 M | 598 K | 181 K | 3.01 M | 18.8 K | 18.8 K | 18.8 K | 18.8 K | 4.38 K | 158 | 336 | 336 | 251 K | 123 | 803 | - |
Book Value |
-9.55 M | -13.5 M | -13 M | -13.5 M | -13 M | -21.3 M | 88.4 M | 82.1 M | 98.1 M | 132 M | 169 M | 43.6 M | 46.7 M | 46.5 M | 66.1 M | - | - | 72.6 M | 161 M | 166 M | 184 M | 175 M | 178 M | 162 M | 164 M | 166 M | 166 M | 171 M | 172 M | 173 M | 173 M | 155 M | 158 M | 150 M | 152 M | 1.85 M | 2.76 M | 1.53 M | 1.53 M | -1.28 M | -798 K | -637 K | -637 K | 442 K | 717 K | 1.08 M | 1.08 M | 3.48 M | -2.38 M | -2.63 M | 3.48 M | -1.68 M | -1.68 M | -1.68 M | -1.68 M | -4.37 M | 15.5 K | 13.6 K | 13.6 K | 13.3 K | 20.9 K | - | - |
Total Shareholders Equity |
-9.55 M | -13.5 M | -13 M | -13.5 M | -13 M | -21.3 M | 88.4 M | 82.1 M | 98.1 M | 132 M | 134 M | 43.6 M | 46.7 M | 46.5 M | 66.1 M | 66.9 M | 70.3 M | 72.6 M | 161 M | 166 M | 167 M | 166 M | 167 M | 162 M | 162 M | 162 M | 164 M | 171 M | 171 M | 171 M | 172 M | 155 M | 149 M | 149 M | 154 M | 1.85 M | 2.76 M | 1.85 M | 2.76 M | -1.28 M | -798 K | -637 K | -637 K | 442 K | 717 K | 1.08 M | 1.08 M | 3.48 M | -2.38 M | -2.63 M | 3.48 M | -1.68 M | -1.68 M | -1.68 M | -1.68 M | -4.37 M | -31.7 K | -24.7 K | -13.7 K | -9.27 K | 2.08 K | -8.74 K | -8.74 K |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Enochian Biosciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
